A Phase 2 interventional study of BPL-003 and BPL-003 in Treatment Resistant Depression, sponsored by Beckley Psytech Limited. Completed at 42 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Beckley Psytech Limited (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.
Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 34th largest by enrollment of the 181 interventional ones that give a count, is one of 12 that started in 2023, is one of 52 in phase 2, and was the 155th registered.
448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →43 of the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:
NeuroRx, Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 22–60
Motif Neurotech, Inc. · Sites in United States
Ages 22–85
BrainHealth Solutions, Inc. · Sites in United States
Ages 65+
Mclean Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
204 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 58 · Phase 3 23 · Phase 4 17
First in 2001; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 196 is above the median of 59 across 372 interventional studies indexed under Depressive Disorder, Treatment-Resistant.
Median enrollment 38 across the 181 interventional studies, 83 across the 22 observational. Of the 119 that completed or were terminated, 70 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 204 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beckley Psytech Limited, one of the names counted as Eli Lilly and Company. Under that name alone:
Beckley Psytech Limited is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Eli Lilly and Company has 5 studies filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
20 of the studies in Depressive Disorder, Treatment-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT04684706University of PennsylvaniaCompressed Intermittent Theta Burst Stimulation | 2026-11-30 |
| NCT06938841University of California, San DiegoMaintenance rTMS for Depression (Maitr-De) | 2026-11-30 |
| NCT03573349Mayo ClinicKetamine Associated ACC GABA and Glutamate Change and Depression Remission: | 2026-12 |
| NCT07310381Stanford UniversityVagus Nerve Stimulation (VNS) Electroencephalogram (EEG) Protocol Supplement | 2026-12-31 |
Add all 20 to your calendar (.ics) → With an account.
Among the 204 studies in Depressive Disorder, Treatment-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
During the main part of the trial, approximately 200 eligible participants will receive a either a low (sub-therapeutic), medium, or high single dose of BPL-003, given intranasally, with 8 weeks of follow-up assessments.
Following this, participants may receive a second high dose of BPL-003 during the OLE, given intranasally as either a single spray or two sprays 10 minutes apart, with another 8 weeks of follow-up assessments.
Psychological support will be given before, during, and after each dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
1. Other co-morbidities.
Active placebo comparator
Drug: BPL-003
Drug: BPL-003
Drug: BPL-003
Drug: BPL-003
Drug: BPL-003
Core: Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Day 29 (12 mg vs 0.3 mg BPL-003)
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 12 mg (high dose) vs 0.3 mg (low dose) BPL-003 at Day 29 was assessed.
Time frame: 4 weeks
OLE: Number of Participants With Treatment-emergent Adverse Events in the OLE
The safety of a second dose of BPL-003 given with psychological support to participants with TRD was assessed by the number and percentage of participants with treatment-emergent adverse events.
Time frame: 8 weeks
Core: Change From Baseline in MADRS Total Score at Day 8 (12 mg vs 0.3 mg BPL-003)
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 12 mg (high dose) vs 0.3 mg (low dose) BPL-003 at Day 8 was assessed.
Time frame: 1 week
Core: Change From Baseline in MADRS Total Score at Day 29 (8 mg vs 0.3 mg BPL-003)
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 8 mg (medium dose) vs 0.3 mg (low dose) BPL-003 at Day 29 was assessed.
Time frame: 4 weeks
Core: Change From Baseline in MADRS Total Score at Day 8 (8 mg vs 0.3 mg BPL-003)
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 8 mg (medium dose) vs 0.3 mg (low dose) BPL-003 at Day 8 was assessed.
Time frame: 1 week
Core: Number of Participants With Treatment-emergent Adverse Events in the Core Trial Period
The safety of BPL-003 given with psychological support to participants with TRD was assessed by the number and percentage of participants with treatment-emergent adverse events. Any clinically significant findings during the trial have been included as adverse events.
Time frame: 8 weeks
Participants were recruited to the study between 14-Sep-2023 and 20-Jan-2025.
| Milestone | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) | Core: High Dose (12 mg) | OLE: Monophasic Dosing (12 mg) | OLE: Biphasic Dosing (4 mg and 8 mg) |
|---|---|---|---|---|---|
| Started | 74 | 46 | 73 | 0 | 0 |
| Completed | 64 | 41 | 69 | 0 | 0 |
| Not completed | 10 | 5 | 4 | 0 | 0 |
| Milestone | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) | Core: High Dose (12 mg) | OLE: Monophasic Dosing (12 mg) | OLE: Biphasic Dosing (4 mg and 8 mg) |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 53 | 54 |
| Completed | 0 | 0 | 0 | 48 | 47 |
| Not completed | 0 | 0 | 0 | 5 | 7 |
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 12 mg (high dose) vs 0.3 mg (low dose) BPL-003 at Day 29 was assessed.
| Units on a scale | Core: Low Dose (0.3 mg) | Core: High Dose (12 mg) |
|---|---|---|
| Core: Change From Baseline in Montgomery and Asberg Depression Rating Scale (MADRS) Total Score at Day 29 (12 mg vs 0.3 mg BPL-003) | -5.8 ± 1.28 | -11.2 ± 1.27 |
The safety of a second dose of BPL-003 given with psychological support to participants with TRD was assessed by the number and percentage of participants with treatment-emergent adverse events.
| Participants | OLE: Monophasic Dosing (12 mg) | OLE: Biphasic Dosing (12 mg) |
|---|---|---|
| OLE: Number of Participants With Treatment-emergent Adverse Events in the OLE | 46 | 46 |
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 12 mg (high dose) vs 0.3 mg (low dose) BPL-003 at Day 8 was assessed.
| Units on a scale | Core: Low Dose (0.3 mg) | Core: High Dose (12 mg) |
|---|---|---|
| Core: Change From Baseline in MADRS Total Score at Day 8 (12 mg vs 0.3 mg BPL-003) | -4.7 ± 1.20 | -10.9 ± 1.19 |
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 8 mg (medium dose) vs 0.3 mg (low dose) BPL-003 at Day 29 was assessed.
| Units on a scale | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) |
|---|---|---|
| Core: Change From Baseline in MADRS Total Score at Day 29 (8 mg vs 0.3 mg BPL-003) | -5.8 ± 1.28 | -12.0 ± 1.61 |
The MADRS is a 10-item diagnostic questionnaire used to measure the severity of depressive episodes in participants with mood disorders. The MADRS was administered remotely throughout the trial by independent, centralized, qualified raters. The rater used the SIGMA to interview the participant, moving from broadly based questions about symptoms to more detailed questions that allowed the precise rating of symptom severity. The SIGMA provides structured probes to ensure standardization of administration and comprehensiveness of coverage of the 10 items of the scale. A higher MADRS score indicates more severe depression, with each item yielding a score of 0-6. Total overall scores therefore range from 0-60. The change from baseline in MADRS total score for 8 mg (medium dose) vs 0.3 mg (low dose) BPL-003 at Day 8 was assessed.
| Units on a scale | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) |
|---|---|---|
| Core: Change From Baseline in MADRS Total Score at Day 8 (8 mg vs 0.3 mg BPL-003) | -4.7 ± 1.20 | -11.0 ± 1.52 |
The safety of BPL-003 given with psychological support to participants with TRD was assessed by the number and percentage of participants with treatment-emergent adverse events. Any clinically significant findings during the trial have been included as adverse events.
| Participants | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) | Core: High Dose (12 mg) |
|---|---|---|---|
| Core: Number of Participants With Treatment-emergent Adverse Events in the Core Trial Period | 54 | 35 | 62 |
Collected over Core period: 8 weeks; OLE period: 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Core: Low Dose (0.3 mg) | 0/74 (0%) | 1/74 (1.4%) | 54/74 (73%) |
| Core: Medium Dose (8 mg) | 0/46 (0%) | 1/46 (2.2%) | 35/46 (76.1%) |
| Core: High Dose (12 mg) | 0/73 (0%) | 0/73 (0%) | 62/73 (84.9%) |
| OLE: Monophasic Dosing (12 mg) | 0/53 (0%) | 2/53 (3.8%) | 46/53 (86.8%) |
| OLE: Biphasic Dosing (4 mg or 12 mg) | 0/54 (0%) | 1/54 (1.9%) | 39/54 (72.2%) |
| Event | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) | Core: High Dose (12 mg) | OLE: Monophasic Dosing (12 mg) | OLE: Biphasic Dosing (4 mg or 12 mg) |
|---|---|---|---|---|---|
| AgitationPsychiatric disorders | 0/74 | 1/46 | 0/73 | 0/53 | 0/54 |
| Suicidal ideationPsychiatric disorders | 0/74 | 0/46 | 0/73 | 1/53 | 1/54 |
| Binge drinkingPsychiatric disorders | 0/74 | 0/46 | 0/73 | 1/53 | 0/54 |
| DepressionPsychiatric disorders | 1/74 | 0/46 | 0/73 | 0/53 | 0/54 |
| Event | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) | Core: High Dose (12 mg) | OLE: Monophasic Dosing (12 mg) | OLE: Biphasic Dosing (4 mg or 12 mg) |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 2/74 | 15/46 | 29/73 | 20/53 | 14/54 |
| HeadacheNervous system disorders | 21/74 | 12/46 | 24/73 | 16/53 | 13/54 |
| AnxietyPsychiatric disorders | 6/74 | 2/46 | 12/73 | 13/53 | 4/54 |
| Administration site painGeneral disorders | 6/74 | 8/46 | 16/73 | 9/53 | 9/54 |
| Administration site discomfortGeneral disorders | 2/74 | 5/46 | 12/73 | 7/53 | 11/54 |
| Blood pressure increasedInvestigations | 3/74 | 6/46 | 12/73 | 5/53 | 8/54 |
| VomitingGastrointestinal disorders | 3/74 | 6/46 | 9/73 | 4/53 | 8/54 |
| InsomniaPsychiatric disorders | 6/74 | 1/46 | 9/73 | 5/53 | 5/54 |
| FatigueGeneral disorders | 0/74 | 1/46 | 4/73 | 4/53 | 6/54 |
| Psychomotor hyperactivityNervous system disorders | 0/74 | 0/46 | 4/73 | 5/53 | 6/54 |
The overall trial population comprised 300 participants, including 193 participants in the Core trial period, of whom 107 continued into the OLE trial period. Baseline characteristics are presented for the full analysis set (FAS) for each trial period, defined as all participants who were randomized and received at least 1 dose of trial medication during the respective trial period. The FAS comprises 193 participants for the Core Trial Period and 107 participants for the OLE trial period.
| Age, Continuous(Years) | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) | Core: High Dose (12 mg) | OLE: Monophasic Dosing (12 mg) | OLE: Biphasic Dosing (4 mg and 8 mg) | Total |
|---|---|---|---|---|---|---|
| Core trial period | 41.0 ± 11.17 | 40.6 ± 12.10 | 41.2 ± 10.59 | — | — | 41.2 ± 11.13 |
| OLE trial period | — | — | — | 40.4 ± 9.10 | 39.6 ± 10.95 | 40.0 ± 10.04 |
| Sex: Female, Male(Participants) | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) | Core: High Dose (12 mg) | OLE: Monophasic Dosing (12 mg) | OLE: Biphasic Dosing (4 mg and 8 mg) | Total |
|---|---|---|---|---|---|---|
| Core trial period — Female | 44 | 27 | 43 | 0 | 0 | 114 |
| Core trial period — Male | 30 | 19 | 30 | 0 | 0 | 79 |
| OLE trial period — Female | 0 | 0 | 0 | 29 | 33 | 62 |
| OLE trial period — Male | 0 | 0 | 0 | 24 | 21 | 45 |
| Race (NIH/OMB)(Participants) | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) | Core: High Dose (12 mg) | OLE: Monophasic Dosing (12 mg) | OLE: Biphasic Dosing (4 mg and 8 mg) | Total |
|---|---|---|---|---|---|---|
| Core trial period — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Core trial period — Asian | 3 | 3 | 5 | 0 | 0 | 11 |
| Core trial period — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Core trial period — Black or African American | 4 | 5 | 1 | 0 | 0 | 10 |
| Core trial period — White | 67 | 38 | 66 | 0 | 0 | 171 |
| Core trial period — More than one race | 0 | 0 | 1 | 0 | 0 | 1 |
| Core trial period — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| OLE trial period — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| OLE trial period — Asian | 0 | 0 | 0 | 0 | 3 | 3 |
| OLE trial period — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| OLE trial period — Black or African American | 0 | 0 | 0 | 1 | 2 | 3 |
| OLE trial period — White | 0 | 0 | 0 | 51 | 49 | 100 |
| OLE trial period — More than one race | 0 | 0 | 0 | 1 | 0 | 1 |
| OLE trial period — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Core: Low Dose (0.3 mg) | Core: Medium Dose (8 mg) | Core: High Dose (12 mg) | OLE: Monophasic Dosing (12 mg) | OLE: Biphasic Dosing (4 mg and 8 mg) | Total |
|---|---|---|---|---|---|---|
| Core trial period — Hispanic or Latino | 6 | 3 | 3 | 0 | 0 | 12 |
| Core trial period — Not Hispanic or Latino | 68 | 43 | 70 | 0 | 0 | 181 |
| Core trial period — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| OLE trial period — Hispanic or Latino | 0 | 0 | 0 | 5 | 1 | 6 |
| OLE trial period — Not Hispanic or Latino | 0 | 0 | 0 | 48 | 53 | 101 |
| OLE trial period — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Due to the GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion
Ran from Sep 2023 to primary completion in Mar 2025, 18 months.
Results were first posted in Sep 2026, 1 year 5 months after primary completion.
Of 50 phase 2 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BPL-003
Depressive Disorder, Treatment-Resistant →